Publicaciones 2013
  1. Catalá López F, Gènova R, Peiró S. Global health priorities and research funding. Lancet Infect Dis. 2013. 13(8):652. [IF: 19,996; Q:1; LETTER] 
     
  2. Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD; for the Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. The Incidence of AIDS-Defining Illnesses at a Current CD4 Count >=200 Cells/μL in the Post-Combination Antiretroviral Therapy Era. Clin Infect Dis. 2013;57(7):1038-47. [IF: 9,374; Q:1] 
     
  3. Sanfélix-Gimeno G, Sanfélix-Genovés J, Rodriguez-Bernal CL, Peiró S, Hurtado I. Prevalence, determinants and inappropriateness of calcium supplementation among men and women in a Spanish Mediterranean area. Cross-sectional data from the ESOSVAL cohort. J Bone Mineral Res. 2013;28(11):2286-94. [IF: 6,128; Q:1] 
     
  4. Sanfélix-Genovés J, Sanfélix-Gimeno G, Peiró S, Hurtado I, Fluixà C, Fuertes A, Campos JC, Giner V, Baixauli C. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort. Osteoporos Int. 2013;24(3):1045-55. [IF: 4,039; Q:1]
     
  5. Catalá-López F, Sanfélix-Gimeno G, Tobías A, Hurtado I, Sanfélix-Genovés J, Peiró S. Efficacy of osteoporosis therapies in a network meta-analysis with indirect comparisons: many concerns for new tools of evidence synthesis? Osteoporos Int. 2013; 24(6):1927-8. [IF: 4,039; Q:1; LETTER ] 
     
  6. Sanfélix-Genovés J, Hurtado I, Sanfélix-Gimeno G, Peiró S. Prevalence of osteoporosis in the ESOSVAL cohort: reply to the comment by Pedrera-Zamorano et al. Osteoporos Int. 2013;24(6):1925-6. [IF: 4,039; Q:1; LETTER] 
     
  7. Catalá-López F, Sanfélix-Gimeno G, Ridao M, Peiró S. When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins. PLoS One. 2013;8(7):e69462. [IF: 3,730; Q:1] 
     
  8. Sanfélix-Gimeno G, Sanfelix-Genovés J, Hurtado I, Reig-Molla B, Peiró S. Vertebral fracture risk factors in postmenopausal women over 50 in Valencia, Spain. A population-based cross-sectional study. Bone. 2013;52(1):393-9. [IF: 3,823; Q:1] 
     
  9. Catalá-López F, Sanfélix-Gimeno G, Ridao M, Peiró S. Trends of uncontrolled blood pressure in Spain: an updated meta-regression analysis. J Hypertens. 2013;31(3):630-1. [IF: 3,806; Q:1; LETTER] 
     
  10. Rojas LE, Herrero MJ, Bosó V, García-Eliz M, Poveda JL, Librero J, Aliño SF. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation. Pharmacogenet Genomics. 2013;23(10):509-517. [IF: 3,608; Q:?] 
     
  11. Franklin JM, Shrank WH, Pakes J, Sanfélix-Gimeno G, Matlin OS, Brennan TA, Choudhry NK. Group-based trajectory models accurately summarized observed patterns of medication adherence. Med Care. 2013; 51(9):789-96. [IF: 3,411; Q:1] 
     
  12. Catalá-López F, Macías Saint-Gerons D. Diabetes Mellitus and Risks of Dual Blockade of the Renin-angiotensin-aldosterone System. Rev Esp Cardiol. 2013 66(5):412-5. [IF: 3,204; Q:2; LETTER] 
     
  13. Catalá-López F. Evaluation of Comparative Treatment Effects Using Indirect Comparisons. Rev Esp Cardiol. 2013;66(2):156-157. [IF: 3,204; Q:2; LETTER] 
     
  14. Sanfélix-Gimeno G, Ferreros I, Pérez-Vicente R, Librero J, Catalá-López F, Peiró S. Adherence to evidence-based therapies after discharge among patients with acute coronary syndromes. A retrospective population-based study linking health information systems in Valencia, Spain. J Manage Care Pharm. 2013;19(3):247-57. [IF: 2,250; Q:2] ORIGINAL 
     
  15. Catalá-López F, Gènova-Maleras R, Ridao M, Alvarez E, Sanfélix-Gimeno G, Morant C, Peiró S. Burden of disease assessment with summary measures of population health for the Region of Valencia, Spain: a population-based study. Med Clin (Barc). 2013;140(8):343-50. [IF: 1,399; Q:2] 
     
  16. Sanfélix-Gimeno G. [Opportunities for improvement in the management of osteoporosis. Time to tackle the essential]. Med Clin (Barc). 2013;141(12):527-8. [IF: 1,399; Q:2; EDITORIAL] 
     
  17. Rodríguez-Martínez P, Peiró S, Librero J, Bernal-Delgado E, Gisbert-Grifo M, Calabuig-Pérez J, Ridao-López M, Sanfélix-Gimeno G. Carpal tunnel release surgery: small-area variation and impact of ambulatory surgery in the autonomous  region of Valencia, Spain. Gac Sanit. 2013;27(3):214-9. [IF: 1,116; Q:3] 
     
  18. Santos-Ramos B, Fernández-Fernández R, Marín-Gil R, Espinosa-Bosch M, Peiró-Moreno S, Pérez-Guerrero C, Bautista-Paloma J. Use of monoclonal antibodies for metastatic colorectal cancer in the Andalusian public health system. Int J Clin Pharm. 2013. 35(4):550-3. [IF: 1,265; Q:?] 
     
  19. Cano-Blanquer D, Cervera-Casino P, Peiró-Moreno S, Mateu-García M, Barreda-Aznar A; Grupo de Estudio de la Automonitorización Glucémica. [Prevalence and Associated Factors in Self-Monitoring of Blood Glucose in Noninsulin-treated Type 2 Diabetes Patients in the Valencia Community, Spain]. Rev Esp Salud Publica. 2013;87(2):149-63. [IF: 0,774; Q:4]. 
     
  20. Bonet Plá A,  Gosalbes Soler V, Ridao-López M, Navarro-Pérez J, Navarro Cubells B, Peiró S. Dabigatran vs. Acenocumarol para la prevención del ictus en la fibrilación atrial. Análisis de impacto presupuestario en un Departamento Sanitario. Rev Esp Salud Pública. 2013;87:331-42. [IF: 0,774; Q:4] 
     
  21. Moro Valdezate D, Peiró S, Buch-Villa E, Caballero-Gárate A, Morales-Monsalve MD, Martínez-Agulló A, Checa-Ayet F, Ortega-Serrano J. Evolution of Health-Related Quality of Life in Breast Cancer Patients during the First Year of Follow-Up. J Breast Cancer. 2013; 16(1):104-111. [IF: 0,318; Q:4] 
     
  22. Catalá-López F, Ridao M, Sanfélix-Gimeno G, Peiró S. Cost-effectiveness of pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: Qualitative synthesis of scientific evidence. Rev Psiquiatr Salud Ment. 2013;6(4):168-77 [IF: 0,308; Q:4] 
     
  23. Peiró S. No llegar o pasarse. A propósito del Real Decreto-Ley 16/2012. Form Med Cont Aten Primaria. 2013; 20(8)441-5. [NOT JCR INDEXED]
     
  24. Oliva J, Peiró S, Puig-Junoy J. Horizontes de cambio en el Sistema Nacional de Salud: agenda para una reforma sanitaria ordenada. Economistas. 2013; (136):6-14. [NOT JCR INDEXED].
     
  25. Oliva J, Peiró S, Puig-Junoy J. Sistema Nacional de Salud y propuesta de reformas: más allá del ruido y la furia. Derecho y Salud. 2013; 23(Extra):6-18. [NOT JCR INDEXED]
     
  26. Espín Balbino J, Abellán Perpiñán JM, Peiró Moreno S, Gómez Pajuelo P. Garantía, Solvencia y Sostenibilidad del Sistema Nacional de Salud Español: Análisis Cualitativo desde la Farmacia Hospitalaria. Madrid: Fundación Gaspar Casal; 2013. [ISBN: 84-695-7549-X]
     
  27. Peiró S, Meneu R. Gestión de la utilización. En: Ríos JF, Schiavone MA, eds. Economía y financiamiento de la salud. Ayacucho, AR: Editorial Dunken; 2013. pp 97-120. [ISBN: en trámite]
     
  28. Puig-Junoy J, Peiró S. De la utilidad de los medicamentos al valor terapéutico añadido y a la relación coste-efectividad incremental. En: Ríos JF, Schiavone MA, eds. Economía y financiamiento de la salud. Ayacucho, AR: Editorial Dunken; 2013. pp 288-301. [ISBN: en trámite]